Initial Statement of Beneficial Ownership (3)
April 09 2021 - 4:05PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DeLong Mark Jeffrey |
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/30/2021
|
3. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [APLS]
|
(Last)
(First)
(Middle)
C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Senior Vice President / |
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 8698 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | (1) | 1/27/2031 | Common Stock | 30000 | $44.90 | D | |
Stock Option (Right to Buy) | (1) | 2/9/2030 | Common Stock | 18750 | $44.33 | D | |
Stock Option (Right to Buy) | (1) | 2/4/2028 | Common Stock | 50000 | $15.52 | D | |
Stock Option (Right to Buy) | (1) | 2/27/2029 | Common Stock | 30000 | $13.85 | D | |
Explanation of Responses: |
(1) | This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
DeLong Mark Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM, MA 02451 |
|
| Senior Vice President |
|
Signatures
|
/s/ David Watson, attorney-in-fact for Mark Delong | | 4/9/2021 |
**Signature of Reporting Person | Date |
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Sep 2023 to Sep 2024